Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A fluoride-containing dentifrice developed and marketed by GSK, most notably under the Sensodyne brand for the management of dentin hypersensitivity. The formulation typically contains sodium monofluorophosphate (SMFP) as the active ingredient, often at a concentration of 1000 ppm fluoride. Its primary therapeutic role is the prevention of dental caries and the promotion of enamel remineralization; fluoride ions incorporate into the tooth structure to form fluorapatite, which is more resistant to acid-induced demineralization than naturally occurring hydroxyapatite. In clinical trials for dentin sensitivity, this toothpaste is frequently utilized as a standardized background treatment or a control arm to isolate the efficacy of adjunct desensitizing agents, such as dipotassium oxalate or potassium nitrate, which may be delivered through experimental oral rinses or specialized toothpaste variants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium monofluorophosphate toothpaste.